Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMND NASDAQ:EVFM NASDAQ:INM NASDAQ:ONCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$1.03+0.6%$1.02$0.80▼$2.18$4.35M0.9734,534 shs37,361 shsEVFMEvofem Biosciences$0.02-1.9%$0.01$0.01▼$0.02$1.80M-1.11427,601 shs766,939 shsINMInMed Pharmaceuticals$2.22+3.7%$2.40$1.72▼$8.27$4.28M0.2936,196 shs114,093 shsONCOOnconetix$3.10+1.6%$3.31$2.61▼$552.50$4.71M3.3645,814 shs18,322 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine0.00%-0.97%-0.97%+17.24%-23.88%EVFMEvofem Biosciences0.00%+55.00%+64.89%+66.67%+70.33%INMInMed Pharmaceuticals0.00%+1.42%-7.76%-9.70%-59.07%ONCOOnconetix0.00%+9.71%+4.10%-28.40%-99.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$1.03+0.6%$1.02$0.80▼$2.18$4.35M0.9734,534 shs37,361 shsEVFMEvofem Biosciences$0.02-1.9%$0.01$0.01▼$0.02$1.80M-1.11427,601 shs766,939 shsINMInMed Pharmaceuticals$2.22+3.7%$2.40$1.72▼$8.27$4.28M0.2936,196 shs114,093 shsONCOOnconetix$3.10+1.6%$3.31$2.61▼$552.50$4.71M3.3645,814 shs18,322 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine0.00%-0.97%-0.97%+17.24%-23.88%EVFMEvofem Biosciences0.00%+55.00%+64.89%+66.67%+70.33%INMInMed Pharmaceuticals0.00%+1.42%-7.76%-9.70%-59.07%ONCOOnconetix0.00%+9.71%+4.10%-28.40%-99.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMNDClearmind Medicine 0.00N/AN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/AINMInMed Pharmaceuticals 0.00N/AN/AN/AONCOOnconetix 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AEVFMEvofem Biosciences$11.39M0.16N/AN/A($2.64) per share-0.01INMInMed Pharmaceuticals$4.60M0.97N/AN/A$20.64 per share0.11ONCOOnconetix$2.52M1.91N/AN/A$11.22 per share0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMNDClearmind Medicine-$5.26M-$0.76N/A∞N/AN/A-173.87%-70.55%9/15/2025 (Estimated)EVFMEvofem Biosciences$52.98M-$0.07N/A∞N/A-46.42%-91.97%-61.93%N/AINMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-168.87%-107.93%-82.97%9/26/2025 (Estimated)ONCOOnconetix-$58.69MN/A0.00∞N/A-3,327.03%-192.74%-89.55%N/ALatest EVFM, CMND, INM, and ONCO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q3 2025CMNDClearmind MedicineN/A-$0.25N/A-$0.25N/AN/A8/14/2025Q2 2025ONCOOnconetixN/A-$4.05N/A-$4.76N/A$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMNDClearmind MedicineN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMNDClearmind MedicineN/A1.321.32EVFMEvofem BiosciencesN/A0.110.09INMInMed Pharmaceuticals0.063.493.04ONCOOnconetixN/A0.070.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMNDClearmind Medicine96.05%EVFMEvofem Biosciences0.22%INMInMed Pharmaceuticals20.12%ONCOOnconetix23.89%Insider OwnershipCompanyInsider OwnershipCMNDClearmind MedicineN/AEVFMEvofem Biosciences0.01%INMInMed Pharmaceuticals1.43%ONCOOnconetix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableINMInMed Pharmaceuticals102.00 million1.97 millionNot OptionableONCOOnconetix121.55 million1.50 millionN/AEVFM, CMND, INM, and ONCO HeadlinesRecent News About These CompaniesOnconetix Director Resignation Amid Financial AdjustmentsAugust 12, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)July 17, 2025 | globenewswire.comOnconetix, Inc.: Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | finanznachrichten.deOnconetix Shares Touch All-Time Low on Reverse Merger With OcuvexJuly 16, 2025 | marketwatch.comONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to ShareholdersJuly 16, 2025 | businesswire.comOnconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | globenewswire.comOnconetix, Inc. Announces Positive Decision by Nasdaq Hearings PanelJune 16, 2025 | globenewswire.comOnconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by StockholdersJune 13, 2025 | nasdaq.comOnconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of StockholdersJune 11, 2025 | globenewswire.comOnconetix faces potential Nasdaq delisting over filing delaysMay 24, 2025 | investing.comOnconetix receives additional delisting notice from NasdaqMay 23, 2025 | finance.yahoo.comOnco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision OncologyMay 22, 2025 | accessnewswire.comAOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqMay 22, 2025 | globenewswire.comOnco-Innovations Uplists to Cboe CanadaMay 22, 2025 | businesswire.comOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqApril 30, 2025 | globenewswire.comOnconetix faces third delisting threat since 2022 IPOApril 21, 2025 | bizjournals.comOnco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP TechnologyApril 17, 2025 | accessnewswire.comAOnco-Innovations Announces Private PlacementApril 16, 2025 | accessnewswire.comAOnconetix Inks Letter Of Intent For Potential Business Combination With OcuvexApril 10, 2025 | nasdaq.comFive things you need to know today, and calming irrational fearsApril 9, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20253 Big Dividend Hikes Hit the Market—1 Just Doubled Its PayoutBy Leo Miller | September 8, 2025Tencent Music Stock Outshines Spotify as China’s Music GiantBy Leo Miller | August 31, 2025EVFM, CMND, INM, and ONCO Company DescriptionsClearmind Medicine NASDAQ:CMND$1.03 +0.01 (+0.64%) Closing price 03:58 PM EasternExtended Trading$1.02 -0.01 (-0.54%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Evofem Biosciences NASDAQ:EVFM$0.02 0.00 (-1.94%) As of 03:59 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.InMed Pharmaceuticals NASDAQ:INM$2.22 +0.08 (+3.74%) Closing price 03:59 PM EasternExtended Trading$2.20 -0.02 (-1.08%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Onconetix NASDAQ:ONCO$3.10 +0.05 (+1.64%) Closing price 03:58 PM EasternExtended Trading$3.10 0.00 (-0.16%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
